Evidence map›Paper›PMID 24786948›Full record

Trial reportThe international journal of neuropsychopharmacology2014

GRIK1 genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink.

Henry R Kranzler, Stephen Armeli, Richard Feinn, Howard Tennen, Joel Gelernter, Jonathan Covault

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The international journal of neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Posttreatment effects of topiramate treatment for heavy drinking.Alcoholism, clinical and experimental research · 2014
    Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Pharmacogenetics of alcohol addiction: current perspectives.The application of clinical genetics · 2019
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Henry R KranzlerCenter for Studies of Addiction, Department of Psychiatry,Perelman School of Medicine of the University of Pennsylvania and VISN4 MIRECC,Philadelphia VAMC, Philadelphia,PA, USA.
Stephen ArmeliDepartment of Psychology,Fairleigh Dickinson University,Teaneck,NJ, USA.
Richard FeinnFrank Netter School of Medicine,Quinnipiac University,Hamden,CT, USA.
Howard TennenDepartment of Community Medicine and Healthcare,University of Connecticut School of Medicine,Farmington,CT, USA.
Joel GelernterDepartment of Psychiatry,Yale University School of Medicine,New Haven, CT and VA Connecticut Healthcare, West Haven,CT, USA.
Jonathan CovaultAlcohol Research Center, Department of Psychiatry,University of Connecticut School of Medicine,Farmington,CT, USA.
University of Connecticut · USFairleigh Dickinson University · USQuinnipiac University · USUniversity of Pennsylvania · USYale University · US

Funding

Translational Technologies CoreP50AA012870 · NIAAA · YALE UNIVERSITY · PI John H. Krystal · 2001 to 2026
$43.7M
ZONISAMIDE VERSUS PLACEBOM01RR006192 · NCRR · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI CLOUTIER, MICHELLE M. · 1994 to 2008
$22.1M
Vulnerabilities for coping-related drinking among post-college young adultsP60AA003510 · NIAAA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI COVAULT, JONATHAN M · 2008 to 2017
$17.5M
WHO COLLABORATIVE PROJECT ON MANAGEMENT OF HARMFUL ALCOHOL CONSUMPTIONP50AA003510 · NIAAA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI HESSELBROCK, VICTOR M · 1985 to 2007
$13.6M
Pharmacogenetic Analysis of Topiramate Treatment of AUDR01AA023192 · NIAAA · UNIVERSITY OF PENNSYLVANIA · PI KRANZLER, HENRY RICHARD · 2014 to 2018
$2.7M
Novel Approaches to Alcoholism Pharmacotherapy and RiskK24AA013736 · NIAAA · UNIVERSITY OF PENNSYLVANIA · PI KRANZLER, HENRY RICHARD · 2002 to 2012
$1.5M
NCRR NIH HHS M01 RR006192NCRR NIH HHS M01 RR06192NIAAA NIH HHS K24 AA013736NIAAA NIH HHS K24 AA13736NIAAA NIH HHS P50 AA003510NIAAA NIH HHS P50 AA012870NIAAA NIH HHS P50 AA12870NIAAA NIH HHS P60 AA003510NIAAA NIH HHS P60 AA03510NIAAA NIH HHS R01 AA023192
6 · The paper itself

Abstract

We (Kranzler et al., 2014) reported that topiramate 200 mg/day reduced heavy drinking days and increased abstinent days in 138 heavy drinkers whose treatment goal was to reduce drinking to safe levels. In that 12-week, placebo-controlled study, we measured drinking using the Timeline Follow-back method at each treatment visit. In addition to the intent-to-treat effects of topiramate, we found that a single nucleotide polymorphism (rs2832407) in GRIK1, encoding the GluK1 subunit of the kainate receptor, moderated the treatment effect in European Americans (EAs; n = 122). Topiramate reduced heavy drinking only in rs2832407*C allele homozygotes. Here, we augment those analyses by using patients' daily reports obtained using interactive voice response technology; (a) to validate the interactive effects of GRIK1 and topiramate as predictors of drinking level; and, (b) to examine changes in expected positive effects of drinking (i.e. positive outcome expectancies) and desire to drink. We found that rs2832407*C allele homozygotes treated with topiramate drank less overall during treatment than those receiving placebo, validating our earlier findings for heavy drinking days (Kranzler et al., 2014). There was also a study day × medication group × genotype group interaction that predicted both positive alcohol expectancies and desire to drink, with rs2832407*C-allele homozygotes treated with topiramate showing the largest decreases in these outcomes during the study period. Changes in positive alcohol expectancies or desire to drink did not mediate the effects on drinking. These findings validate and extend our previous pharmacogenetic findings with topiramate.

Indexed as

Alcohol DrinkingPharmacogeneticsAdultDouble-Blind MethodDrinking BehaviorFemaleFructoseGenotypeHumansKainic Acid ReceptorsMaleMiddle AgedNeuroprotective AgentsPatient CompliancePolymorphism, Single NucleotideProspective StudiesFructoseKainic Acid ReceptorsNeuroprotective AgentsTopiramate

Identifiers

PMID24786948
PMCPMC4161658
OpenAlexW2125146690

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.